Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PPGN.SW
- Price
- 16.88
- Stock movement up
- +0.46 (2.80%)
- Company name
- PolyPeptide Group AG
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 556.76M
- Ent value
- 768.92M
- Price/Sales
- 1.03
- Price/Book
- 1.46
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -21.78%
- Trailing P/E
- -
- Forward P/E
- 43.53
- PEG
- -
- EPS growth
- -
- 1 year return
- -42.93%
- 3 year return
- -40.37%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-02
DIVIDENDS
PPGN.SW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 8.71 |
| Price to FCF | - |
| Price to EBITDA | 24.97 |
| EV to EBITDA | 34.48 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.03 |
| Price to Book | 1.46 |
| EV to Sales | 1.43 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 32.98M |
| EPS (TTM) | -1.28 |
| FCF per share (TTM) | -1.35 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 538.23M |
| Gross profit (TTM) | 44.81M |
| Operating income (TTM) | -20.74M |
| Net income (TTM) | -42.11M |
| EPS (TTM) | -1.28 |
| EPS (1y forward) | 0.39 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 8.33% |
| Operating margin (TTM) | -3.85% |
| Profit margin (TTM) | -7.82% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 95.71M |
| Net receivables | 101.07M |
| Total current assets | 326.60M |
| Goodwill | 0.00 |
| Intangible assets | 16.45M |
| Property, plant and equipment | 498.86M |
| Total assets | 689.09M |
| Accounts payable | 60.91M |
| Short/Current long term debt | 113.66M |
| Total current liabilities | 176.45M |
| Total liabilities | 307.86M |
| Shareholder's equity | 381.23M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 63.94M |
| Capital expenditures (TTM) | 108.34M |
| Free cash flow (TTM) | -44.40M |
| Dividends paid (TTM) | 9.67M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -11.04% |
| Return on Assets | -6.11% |
| Return on Invested Capital | -8.85% |
| Cash Return on Invested Capital | -9.33% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 16.42 |
| Daily high | 16.90 |
| Daily low | 16.42 |
| Daily Volume | 26K |
| All-time high | 143.80 |
| 1y analyst estimate | 36.01 |
| Beta | 1.12 |
| EPS (TTM) | -1.28 |
| Dividend per share | - |
| Ex-div date | 28 Apr 2022 |
| Next earnings date | 10 Apr 2025 |
Downside potential
Loading...
Downside potential data
| PPGN.SW | S&P500 | |
| Current price drop from All-time high | -88.26% | -8.48% |
| Highest price drop | -90.13% | -56.47% |
| Date of highest drop | 19 Jan 2024 | 9 Mar 2009 |
| Avg drop from high | -64.16% | -11.07% |
| Avg time to new high | 41 days | 12 days |
| Max time to new high | 901 days | 1805 days |
COMPANY DETAILS
Marketcap
556.76M
Marketcap category
Small-cap
Description
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications. It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Employees
1277
Website
Investor relations
-
SEC filings
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
PolyPeptide Group AG (XSWX:PPGN) reports a significant EBITDA margin increase and positive free cash flow, setting a strong foundation for future growth.
March 12, 2025
OKLAHOMA CITY & TORRANCE, Calif., January 13, 2025--This new collaboration provides a scalable, integrated solution for developing and manufacturing complex peptide drugs efficiently.
January 13, 2025
MINNEAPOLIS & TORRANCE, Calif., May 13, 2024--Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration and separation products and solutions, and PolyPeptide Grou...
May 13, 2024